Fundraising FoxvenBio Partners — 2021 Investments
8 investments dated 2021 · listed companies and verified rows first · show all
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPDeerfield Management CompanyForesite CapitalFrazier Life SciencesGeneral Catalyst+9 more
.png)
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Board seatCorey GoodmanRichard Gaster· per SEC Form D
Co-investorsAlpha Wave GlobalBioBritLifeSci Venture PartnersJanus Henderson InvestorsREDMILESamsara BioCapital+2 more
San Diego, US
Mark S. Forman(Executive Officer)inMatthew Moore(Executive Officer)inJohn Nuss(Executive Officer)inJigar Choksey(Director)Martin Auster(Executive Officer)inChristopher W. Krueger(Executive Officer)
Board seatAaron RoystonRichard Gaster· per SEC Form D
Co-investorsNew Science VenturesThird Point VenturesWellington ManagementSilverArc PrivatevenBio Global Strategic
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsDecheng CapitalSamsara BioCapitalWestlake Village BioPartnersAccess IndustriesKleiner Perkins
HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories.
AI & Machine LearningBiotechHealthtechMedical DevicesNew York City, US
Ke Cheng(CEO)inLinh Hoang(Chief Executive Officer)inJerry Kuang(Chief Operations Officer)Julie Feldstein(Chief Pathologist)in
Co-investorsAsahi Kasei Corporate Venture CapitalVivo CapitalY CombinatorAvlok CapitalK5 VenturesMicroVentures
MindRhythm develops a portable, non-invasive medical device that uses the Headpulse algorithm and AI to triage stroke patients in the prehospital setting, helping paramedics identify Large Vessel Occlusion strokes and route patients to appropriate hospitals faster.
AI & Machine LearningDeep TechDigital HealthMedical Devices
John Keane(Co-Founder & CEO)inPaul Lovoi(Co-Founder & CTO)inWade Smith(Co-Founder & Chair of the Scientific Advisory Board)
Co-investorsDCVC (Data Collective)York IE
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Founder)inAndrew Bellinger(Executive Officer)Kiran Musunuru(Founder)
BoardJohn Evans(Director)Anthony Philippakis(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalWellington ManagementCasdin Capital+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ablaze Pharmaceuticals
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.